BlackRock, Inc. 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 3,497,766 6.200% | 0 (Unchanged) | Filing |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 3,497,766 6.200% | 2,225,654 (+174.96%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 1,272,112 3.500% | -976,355 (-43.42%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Black Diamond Therapeutics, Inc. BDTX | BlackRock Inc. BLK | 2,248,467 6.200% | 2,248,467 (New Position) | Filing |